Maintenance of the clinical response with long-acting injectable Risperidone in patients with Schizophrenia or schizoaffective disorders.
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2013
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen-Cilag
- 26 Jun 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01888107).
- 26 May 2011 New trial record